Systemic steroidophobia scale for pediatric rheumatology (SSS-PR): development and validation of a novel psychometric tool measuring clinician steroidophobia

Systemic corticosteroids are cornerstone therapies in pediatric inflammatory diseases. Despite their clinical importance, both parents and clinicians may harbor substantial concerns regarding steroid-related adverse effects. While “steroidophobia” has been extensively studied in the context of topical corticosteroids, no validated instrument exists to assess clinician-based attitudes toward systemic corticosteroid use. This study aimed to develop and validate novel psychometric tools to measure systemic steroidophobia among clinicians. A methodological, multicenter study was conducted between June and October 2025 among pediatric rheumatology specialists and fellows. Two draft instruments were developed: the Oral Corticosteroid Phobia Scale (21 items) and the Intravenous Corticosteroid Phobia Scale (22 items). Face and content validity were evaluated through expert review. Item analysis, exploratory and confirmatory factor analyses, internal consistency (Cronbach’s alpha), and test–retest reliability were performed. A total of 121 clinicians participated. After item reduction, the oral scale comprised 15 items and the intravenous scale 16 items, each demonstrating a two-factor structure. The Oral Corticosteroid Phobia Scale explained 63.5% of total variance (Cronbach’s alpha = 0.908), and the Intravenous Corticosteroid Phobia Scale explained 66.4% (Cronbach’s alpha = 0.935). Test–retest reliability was excellent (ICC = 0.902 and 0.930, respectively). Model fit indices indicated good construct validity. Lower phobia scores were observed among clinicians with longer pediatric rheumatology experience. The developed scales demonstrated acceptable validity and reliability for assessing clinician-based systemic steroidophobia. These tools may facilitate a more systematic and objective identification of attitudinal barriers toward corticosteroid use and may serve as formative educational instruments in residency training and continuing medical education. Further validation across different pediatric subspecialties and countries is warranted.

Authors

Institutions

Publication Details

Journal
Pediatric Rheumatology
Published
2026-03-26
DOI
https://doi.org/10.1186/s12969-026-01200-z
Primary Topic
Dermatology and Skin Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Systemic steroidophobia scale for pediatric rheumatology (SSS-PR): development and validation of a novel psychometric tool measuring clinician steroidophobia

Sema Nur Taşkın, Nuray Aktay Ayaz, Sevil Aydoğan Gedik, Zeynep Kasap Acungil et al.
Pediatric Rheumatology
Dermatology and Skin Diseases
article

Systemic steroidophobia scale for pediatric rheumatology (SSS-PR): development and validation of a novel psychometric tool measuring clinician steroidophobia

Sema Nur Taşkın, Nuray Aktay Ayaz, Sevil Aydoğan Gedik, Zeynep Kasap Acungil, Emrah Atay
article en

Abstract

Systemic corticosteroids are cornerstone therapies in pediatric inflammatory diseases. Despite their clinical importance, both parents and clinicians may harbor substantial concerns regarding steroid-related adverse effects. While “steroidophobia” has been extensively studied in the context of topical corticosteroids, no validated instrument exists to assess clinician-based attitudes toward systemic corticosteroid use. This study aimed to develop and validate novel psychometric tools to measure systemic steroidophobia among clinicians. A methodological, multicenter study was conducted between June and October 2025 among pediatric rheumatology specialists and fellows. Two draft instruments were developed: the Oral Corticosteroid Phobia Scale (21 items) and the Intravenous Corticosteroid Phobia Scale (22 items). Face and content validity were evaluated through expert review. Item analysis, exploratory and confirmatory factor analyses, internal consistency (Cronbach’s alpha), and test–retest reliability were performed. A total of 121 clinicians participated. After item reduction, the oral scale comprised 15 items and the intravenous scale 16 items, each demonstrating a two-factor structure. The Oral Corticosteroid Phobia Scale explained 63.5% of total variance (Cronbach’s alpha = 0.908), and the Intravenous Corticosteroid Phobia Scale explained 66.4% (Cronbach’s alpha = 0.935). Test–retest reliability was excellent (ICC = 0.902 and 0.930, respectively). Model fit indices indicated good construct validity. Lower phobia scores were observed among clinicians with longer pediatric rheumatology experience. The developed scales demonstrated acceptable validity and reliability for assessing clinician-based systemic steroidophobia. These tools may facilitate a more systematic and objective identification of attitudinal barriers toward corticosteroid use and may serve as formative educational instruments in residency training and continuing medical education. Further validation across different pediatric subspecialties and countries is warranted.

Pediatric Rheumatology
Tokat Gaziosmanpaşa Üniversitesi (TR), Eskişehir City Hospital (TR), Istanbul University (TR)
Partnerships for the goals
Openalex Percentile: Top 6%
Dermatology and Skin Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.